Clinical trial
Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have…
NCT00486538 · AbbVie (prior sponsor, Abbott), Industry · Completed
Key facts
| NCT number | NCT00486538 |
|---|---|
| Title | Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib |
| Official title | An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib |
| Lead sponsor | AbbVie (prior sponsor, Abbott), Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | ABT-869 |
| Enrollment | 53 |
| Start date | Jun 1, 2007 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2012 |
| First posted | Jun 14, 2007 |
| Last update posted | Jan 4, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: